Publications by authors named "Sarah S N Lau"
Background: The optimal timing of initiating adjuvant temozolomide (TMZ) chemoradiotherapy after surgery in patients with glioblastoma is contentious. This study aimed to determine whether the timing of adjuvant treatment affects their overall survival (OS).
Methods: Consecutive adult patients with histologically-confirmed newly diagnosed glioblastoma treated with adjuvant TMZ chemoradiotherapy across all neurosurgical centers in Hong Kong between 2006 and 2020 were analyzed.
Article Synopsis
- * It involved 1,010 adult patients, finding a stable age standardized incidence rate (1.0 per 100,000) and a median overall survival of 10.6 months, with factors like performance score and treatment types impacting survival.
- * Despite an increase in the use of temozolomide chemoradiotherapy from 39% to 63% of patients, this did not result in a significant improvement in median overall survival between 2006-2010 and 2015-2019.
Introduction: In contrast to standard-of-care treatment of newly diagnosed glioblastoma, there is limited consensus on therapy upon disease progression. The role of resection for recurrent glioblastoma remains unclear. This study aimed to identify factors for overall survival (OS) and post-progression survival (PPS) as well as to validate an existing prediction model.
View Article and Find Full Text PDF